Alzamend Neuro, Inc. last reported quarterly results on Dec 12, 2024, for Q2 FY2024 (the quarter ended Oct 31, 2024): diluted EPS of -$3.61. It usually reports 42–44 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 42–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Dec 12, 2024
42 days after quarter end
|
Q2 FY2024
ended Oct 31, 2024
|
—
|
-1
|
-3.61
|
|
Mar 16, 2023
44 days after quarter end
|
—
ended Jan 31, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALZN (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- DE
- Headquarters
- Atlanta, GA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1677077
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.